The effect of ramipril and telmisartan on serum potassium and its association with cardiovascular and renal events: Results from the ONTARGET trial

Abstract

Aims

In the Ongoing Telmisartan Alone and in Combination with Ramipril Trial (ONTARGET), dual agent renin-angiotensin-aldosterone system (RAAS) blockade with angiotensin-converting-enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs) did not reduce the risk of renal and cardiovascular outcomes compared with the single use of either agent. Dual therapy however increased the incidence of hyperkalemia. We examined risk factors for hyper- and hyokalemia and hypothesized that both would be associated with worse cardiovascular and renal outcomes.

Methods

A post-hoc analysis of the ONTARGET trial comparing dual therapy (ramipril and telmisartan) vs monotherapy (ramipril or telmisartan) was performed. The association between serum potassium at week 6 on cardiovascular and renal outcomes during the 56 months follow-up was assessed by multivariate Cox analysis. The main cardiovascular outcome was the composite of cardiovascular death, myocardial infarction, stroke, or hospitalization for heart failure. The renal outcome was defined as the composite of a doubling of serum creatinine or chronic dialysis.

Results

Six weeks after randomization, hyperkalemia developed in 210 (2.7%) patients on dual therapy vs 264 (1.6%) patients on monotherapy (p < 0.001 vs dual therapy). Hypokalemia developed in 87 (1.1%) patients on dual therapy vs 200 (1.2%)patients on monotherapy. Serum potassium was nonlinearly associated with cardiovascular and renal events with a nadir between 4.0–5.0 mmol/l for cardiovascular and 4.0–4.5 mmol/l for renal events such that subjects above or below these values exhibited higher risks. This association was independent of age, gender, diabetes, estimated glomerular filtration rate, systolic blood pressure and diuretic use.

Conclusions

With the precautions stipulated by the protocol of the ONTARGET trial, hypokalemia and hyperkalemia were infrequent events. Nevertheless, both high and low serum potassium were associated with an increased risk of cardiovascular and renal disease.

Keywords

Dual RAAS blockade potassium hyperkalemia cardiovascular nephropathy

Get full access to this article

View all access options for this article.

References

Yusuf

Sleight

Pogue

. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 2000; 342: 145–153.

Patel

MacMahon

Chalmers

. Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): A randomised controlled trial. Lancet 2007; 370: 829–840.

Dahlof

Devereux

Kjeldsen

. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): A randomised trial against atenolol. Lancet 2002; 359: 995–1003.

Brenner

Cooper

de Zeeuw

. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001; 345: 861–869.

Rardon

Fisch

. Electrolytes and the heart, 8th ed. New York: McGraw Hill Book Co, 1994.

Kunz

Friedrich

Wolbers

. Meta-analysis: Effect of monotherapy and combination therapy with inhibitors of the renin angiotensin system on proteinuria in renal disease. Ann Intern Med 2008; 148: 30–48.

Yusuf

Teo

Pogue

. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med 2008; 358: 1547–1559.

Mann

Schmieder

McQueen

. Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): A multicentre, randomised, double-blind, controlled trial. Lancet 2008; 372: 547–553.

Parving

Brenner

McMurray

. Cardiorenal end points in a trial of aliskiren for type 2 diabetes. N Engl J Med 2012; 367: 2204–2213.

10.

Lambers Heerspink

de Zeeuw

. Dual RAS Therapy Not on Target, but Fully Alive. Nephron Clin Pract 2010; 116: c137–c142.

11.

Teo

Yusuf

Sleight

. Rationale, design, and baseline characteristics of 2 large, simple, randomized trials evaluating telmisartan, ramipril, and their combination in high-risk patients: The Ongoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial/Telmisartan Randomized Assessment Study in ACE Intolerant Subjects with Cardiovascular Disease (ONTARGET/TRANSCEND) trials. Am Heart J 2004; 148: 52–61.

12.

Don

Sebastian

Cheitlin

. Pseudohyperkalemia caused by fist clenching during phlebotomy. N Engl J Med 1990; 322: 1290–1292.

13.

Levey

Bosch

Lewis

. A more accurate method to estimate glomerular filtration rate from serum creatinine: A new prediction equation Modification of Diet in Renal Disease Study Group. Ann Intern Med 1999; 130: 461–470.

14.

Solomon

Shin

Shah

. Effect of the direct renin inhibitor aliskiren on left ventricular remodelling following myocardial infarction with systolic dysfunction. Eur Heart J 2011; 32: 1227–1234.

15.

Harel

Gilbert

Wald

. The effect of combination treatment with aliskiren and blockers of the renin-angiotensin system on hyperkalaemia and acute kidney injury: Systematic review and meta-analysis. Brit Med J 2012; 344: e42–e42.

16.

Smink

Hoekman

Grobbee

. A prediction of the renal and cardiovascular efficacy of aliskiren in ALTITUDE using short-term changes in multiple risk markers. Eur J Prev Cardiol 2013. [Epub ahead of print 25 September 2013. DOI: 10.1038/clpt.2013.191].

17.

Mann

Sleight

. Serum potassium, cardiovascular risk, and effects of an ACE inhibitor: Results of the HOPE study. Clin Nephrol 2005; 63: 181–187.

18.

Desai

Swedberg

McMurray

. Incidence and predictors of hyperkalemia in patients with heart failure: An analysis of the CHARM Program. J Am Coll Cardiol 2007; 50: 1959–1966.

19.

Alderman

Piller

Ford

. Clinical significance of incident hypokalemia and hyperkalemia in treated hypertensive patients in the antihypertensive and lipid-lowering treatment to prevent heart attack trial. Hypertension 2012; 59: 926–933.

20.

Korgaonkar

Tilea

Gillespie

. Serum potassium and outcomes in CKD: Insights from the RRI-CKD cohort study. Clin J Am Soc Nephrol 2010; 5: 762–769.

21.

Miao

Dobre

Heerspink

. Increased serum potassium affects renal outcomes: A post hoc analysis of the Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan (RENAAL) trial. Diabetologia 2011; 54: 44–50.

22.

Einhorn

Zhan

Hsu

. The frequency of hyperkalemia and its significance in chronic kidney disease. Arch Intern Med 2009; 169: 1156–1162.

23.

Weinberg

Appel

Bakris

. Risk of hyperkalemia in nondiabetic patients with chronic kidney disease receiving antihypertensive therapy. Arch Intern Med 2009; 169: 1587–1594.

24.

Frimodt-Moller

Hoj Nielsen

Strandgaard

. Feasibility of combined treatment with enalapril and candesartan in advanced chronic kidney disease. Nephrol Dial Transplant 2010; 25(3): 842–847.

25.

Preston

Afshartous

Garg

. Mechanisms of impaired potassium handling with dual renin-angiotensin-aldosterone blockade in chronic kidney disease. Hypertension 2009; 53: 754–760.

26.

Karet

. Mechanisms in hyperkalemic renal tubular acidosis. J Am Soc Nephrol 2009; 20: 251–254.

27.

Roscioni

de Zeeuw

Bakker

. Management of hyperkalaemia consequent to mineralocorticoid-receptor antagonist therapy. Nat Rev Nephrol 2012; 8: 691–699.

28.

Apperloo

de Zeeuw

de Jong

. Short-term antiproteinuric response to antihypertensive treatment predicts long-term GFR decline in patients with non-diabetic renal disease. Kidney Int Suppl 1994; 45: S174–S178.

29.

Holtkamp

de Zeeuw

Thomas

. An acute fall in estimated glomerular filtration rate during treatment with losartan predicts a slower decrease in long-term renal function. Kidney Int 2011; 80: 282–287.